Friday, May 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

NIAID-Backed Phase 1b Study to Evaluate Broad-Spectrum Antiviral for Dengue

by Global Biodefense Staff
February 1, 2017
Dengue Virus Broad-Spectrum Treatments

A Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B has been initiated by Emergency BioSolutions, according to an announcement by the company on Feb 1.

UV-4B is the lead dengue virus therapeutic candidate in Emergent’s iminosugar library. Iminosugars are small molecule therapeutics that target host glycosidase enzymes leading to reduced virus infectivity in multiple viruses such as dengue, Zika, SARS, and influenza.

This novel host-based mechanism of action allows the potential for broad-spectrum application and a reduced probability of developing drug resistance.

Preclinical studies have shown that UV-4B is active in vitro against all four dengue virus subtypes and in vivo studies have shown improved survival even when dosing was delayed by up to 48 hours post-infection.

The new study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016.

This study is fully funded under development contract HHSN272201100030C with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health of the U.S. Department of Health and Human Services.

Tags: AntiviralsDengueInfluenzaMosquito-BorneNIAIDSARSZika

Related Posts

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Troubling Trends in Physician Vaccine Confidence in the United States
Medical Countermeasures

Troubling Trends in Physician Vaccine Confidence in the United States

April 5, 2022
Northwestern University Researchers Develop Nanoparticle Vaccine Platform
Medical Countermeasures

Northwestern University Researchers Develop Nanoparticle Vaccine Platform

March 22, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC